Clinical Trials Logo

Sarcoma clinical trials

View clinical trials related to Sarcoma.

Filter by:

NCT ID: NCT00199849 Completed - Prostate Cancer Clinical Trials

NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine

Start date: September 27, 2004
Phase: Phase 1
Study type: Interventional

To evaluate the safety of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine given by particle-mediated epidermal delivery (PMED) in patients with tumor types known to express NY-ESO-1 or LAGE-1.

NCT ID: NCT00194766 Completed - Breast Cancer Clinical Trials

Continuous Temozolomide in Patients With Advanced or Metastatic Soft Tissue Sarcoma or Metastatic Breast Cancer

Start date: July 2000
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether treatment with temozolomide can effect the survival of patients with advanced breast cancer or soft tissue sarcoma.

NCT ID: NCT00189137 Completed - Clinical trials for Sarcoma, Soft Tissue

Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma

Start date: August 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore how a sarcoma is affected by and the side effects of a newer combination of chemotherapy drugs(gemcitabine and docetaxel)as compared to a standard combination of chemotherapy drugs, ifosfamide and doxorubicin.

NCT ID: NCT00188422 Completed - Soft Tissue Sarcoma Clinical Trials

Study of Low Dose CT in Sarcoma Patients

Start date: August 2003
Phase: Phase 1
Study type: Interventional

The primary outcome of this study is the detection of lung metastases comparing Low dose CT (LDCT) and Minimum dose CT (MnDCT) with CXR. Hypothesis 1. LDCT and MnDCT have similar sensitivity for the detection of lung nodules (metastases). 2. MnDCT of the thorax detects a larger number of nodules (metastases) than CXR.

NCT ID: NCT00188175 Completed - Sarcoma Clinical Trials

IMRT Lower Limb Soft Tissue Sarcoma

Start date: May 2003
Phase: Phase 2
Study type: Interventional

Intensity-modulated radiation therapy may make wound healing problems less likely by 1)precisely shaping the region of high radiation dose to the shape of the tissue which harbours tumour cells, and 2) precisely shaping the regions of low radiation dose to the shapes of the normal tissues which are more sensitive to radiation effects.

NCT ID: NCT00187174 Completed - Tumors Clinical Trials

Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors

Start date: October 2004
Phase: Phase 1
Study type: Interventional

Patients with recurrent or refractory solid tumors or brain tumors that are unresponsive to conventional therapy, or with no known effective therapy, will be treated. Experiments in the laboratory have shown the experimental drug RAD001C (RAD001, Everolimus) can prevent cells from multiplying. RAD001 is now being tested in diseases such as cancer, in which excessive cell multiplication needs to be stopped. The drug has been tested in adult cancer patients and has been well tolerated by subjects in these studies. It is experimental and, therefore, available in clinical trials.

NCT ID: NCT00165139 Completed - Neuroblastoma Clinical Trials

Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas

Start date: January 1996
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to determine the short and long term side effects of a very intensive treatment, which includes combinations of chemotherapy drugs followed by radiation therapy and two transplants supported by peripheral blood progenitor cells (stem cells), for children with advanced stage neuroblastoma and sarcomas.

NCT ID: NCT00148109 Completed - Sarcoma Clinical Trials

Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas

Start date: June 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore how this cancer is affected by a new medication, cetuximab. Cetuximab is directed towards a protein called EGFR (epidermal growth factor receptor), that is found in some types of cancer. Studies have shown that this drug can be beneficial in patients with colon cancer and has been approved by the US Food and Drug Administration (FDA) for this purpose. The researchers are conducting a study to see if it is beneficial in patients with sarcoma.

NCT ID: NCT00142571 Completed - Clinical trials for Sarcoma, Soft Tissue

Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma

Start date: January 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the drug gemcitabine to two drugs, gemcitabine and docetaxel, to find out which treatment is better for people with sarcomas.

NCT ID: NCT00134641 Completed - Clinical trials for Sarcoma, Soft Tissue

Study of Gemcitabine and Vinorelbine in Soft Tissue Sarcomas

Start date: February 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if the combination of gemcitabine and vinorelbine is effective in treating patients with advanced soft tissue sarcoma.